Small intestinal endocrine cell-derived exosomal ACE2 is associated with amelioration of MASH and may act through suppression of NLRP3 inflammasome activation

Background Metabolic dysfunction-associated steatohepatitis (MASH) has emerged as a leading cause of cirrhosis worldwide, with its incidence showing a persistent upward trend. This epidemiological shift is expected to substantially increase the population with metabolic abnormalities complicated by hepatic impairment, thereby posing significant challenges to the efficacy of current therapeutic strategies. Consequently, elucidating the underlying pathophysiological mechanisms has become imperative, with gut-derived exosomes emerging as a focal point in this endeavor. Methods Exosomes were isolated from conditioned medium of STC-1 small intestinal endocrine cells treated with palmitic acid (PA) or bovine serum albumin (BSA). For MASH modeling, PA-stimulated AML-12 hepatocytes and high-fat diet/low-dose streptozotocin-treated mice were employed for in vitro and in vivo studies, respectively. Exosomal interventions were then administered to evaluate their regulatory effects on hepatocyte function under metabolic stress. ACE2 knockout mice were used to delineate the pivotal role of exosomal ACE2. Results ACE2 was found abundantly expressed in STC-1 cell-derived exosomes under physiological conditions(NCEXO). These exosomes were detectable within AML-12 hepatocytes in vitro and showed pronounced hepatic fluorescence accumulation in vivo . In both in-vitro and in-vivo MASH mouse models, NCEXO administration significantly improved hepatocellular function and attenuated hepatic fibrosis. These protective effects may be associated with ACE2-related inhibition of NLRP3 inflammasome activation. Conclusion ACE2-enriched intestinal exosomes accumulate in the liver and may ameliorate MASH partly through suppression of NLRP3 inflammasome activation. Our study extends the conceptual understanding of gut–liver axis regulation and provides new avenues for MASH prevention and therapeutic development.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-16
DOI
https://doi.org/10.3389/fphar.2026.1998183
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Small intestinal endocrine cell-derived exosomal ACE2 is associated with amelioration of MASH and may act through suppression of NLRP3 inflammasome activation

Zhijun Wu, Yuan Li, Yang SongTao, Fangyu Li et al.
4 links
Frontiers in Pharmacology
Extracellular vesicles in disease
article

Small intestinal endocrine cell-derived exosomal ACE2 is associated with amelioration of MASH and may act through suppression of NLRP3 inflammasome activation

Zhijun Wu, Yuan Li, Yang SongTao, Fangyu Li, Rui Li, Jie Cao, Qi Chen, Yuanyuan Gao
article en

Abstract

Background Metabolic dysfunction-associated steatohepatitis (MASH) has emerged as a leading cause of cirrhosis worldwide, with its incidence showing a persistent upward trend. This epidemiological shift is expected to substantially increase the population with metabolic abnormalities complicated by hepatic impairment, thereby posing significant challenges to the efficacy of current therapeutic strategies. Consequently, elucidating the underlying pathophysiological mechanisms has become imperative, with gut-derived exosomes emerging as a focal point in this endeavor. Methods Exosomes were isolated from conditioned medium of STC-1 small intestinal endocrine cells treated with palmitic acid (PA) or bovine serum albumin (BSA). For MASH modeling, PA-stimulated AML-12 hepatocytes and high-fat diet/low-dose streptozotocin-treated mice were employed for in vitro and in vivo studies, respectively. Exosomal interventions were then administered to evaluate their regulatory effects on hepatocyte function under metabolic stress. ACE2 knockout mice were used to delineate the pivotal role of exosomal ACE2. Results ACE2 was found abundantly expressed in STC-1 cell-derived exosomes under physiological conditions(NCEXO). These exosomes were detectable within AML-12 hepatocytes in vitro and showed pronounced hepatic fluorescence accumulation in vivo . In both in-vitro and in-vivo MASH mouse models, NCEXO administration significantly improved hepatocellular function and attenuated hepatic fibrosis. These protective effects may be associated with ACE2-related inhibition of NLRP3 inflammasome activation. Conclusion ACE2-enriched intestinal exosomes accumulate in the liver and may ameliorate MASH partly through suppression of NLRP3 inflammasome activation. Our study extends the conceptual understanding of gut–liver axis regulation and provides new avenues for MASH prevention and therapeutic development.

Frontiers in PharmacologyVol. 17
Wuhan Union Hospital (CN), Huazhong University of Science and Technology (CN)
Good health and well-being
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon